MP Biomedicals, LLC

29525 Fountain Parkway
Solon, Ohio 44139

Telephone: 440/337-1200
Toll Free: 800/854-0530
Fax: 440/337-1180
mailto: biotech@mpbio.com
web: http://www.mpbio.com

TECHNICAL INFORMATION

Catalog Number: 158753
Thalidomide

Structure:



Molecular Formula: $C_{13}H_{10}N_2O_4$

Molecular Weight: 258.2

CAS # 50-35-1

Synonyms: (±)-N-(2,6-Dioxo-3-piperidinyl)phthalimide; (±)-2-(2,6-Dioxo-3-piperidinyl)- 1H-isoindole-1,3(2H)-dione

Physical Description: White to off white powder

Description: Inhibits HIV-1 replication, FGF-induced angiogenesis, and a-TNF biosynthesis; an immunosuppresive; sedative; teratogen.

CAUTION: Potent Teratogen. Women of reproductive age should avoid any contact with this compound.

Solubility: Soluble in DMSO (56 mg/ml); soluble in a 45% (w/v) aqueous solution of 2-hydroxypropyl-b-cyclodextrin (0.67 mg/ml). Insoluble in water, ethanol.

References:

– *Merck Index*, **12th Ed.**, No. 9390.
– Makonkawkeyoon, S., et al., *J. Pharmacol. Exp. Therap.*, **v. 160**, 189 (1968).
– D'Amato, R.J., et al., "Thalidomide is an inhibitor of angiogenesis." *Proc. Natl. Acad. Sci. USA*, **v. 91**, 4082 (1994).
– Weglicki, W.B., et al., *Mol. Cell. Biochem.*, **v. 129**, 195 (1993).
– Makonkawkeyoon, S., et al., "Thalidomide inhibits the replication of human immunodeficiency virus type 1." *Proc. Natl. Acad. Sci. USA*, **v. 90**, 5974-5978 (1993).
– Braun, A.G., Harding, F.A., Weinreb, S.L., "Teratogen metabolism: Thalidomide activation is mediated by cytochrome P 450." *Toxicol. Appl. Pharmacol.*, **v. 82**, 175-179 (1986).
– Braun, A.G., Weinreb, S.L., "Teratogen metabolism: Activation of thalidomide and thalidomide analogues to products that inhibit the attachment of cells to concanavalin A coated plastic surfaces." *Biochem. Pharmacol.*, **v. 33**, 1471-1477 (1984).